The Golden Week holidays in Japan have come to an end, and we are enjoying fulfilling days surrounded by fresh greenery. We would like to briefly report on our April performance and the forecast for the second quarter.

<Overview>

 * In our Obstetrics and Gynecology division, R&D is progressing smoothly, and we anticipate the completion of multiple functional prototypes by the end of June.

 * Our Consulting division continues to build strong trust with clients. All three projects from the previous period have been extended, and we have secured a fourth new project, resulting in steady revenue growth. We have also launched business model consulting services in English, which have received excellent feedback and requests for additional participants.

 * In our new Cardiovascular division, we have completed applications for two Grants-in-Aid for Scientific Research (Kakenhi). We eagerly await the results, which are expected to be announced between June and July.

<Market Analysis>

 * In May, the International Federation of Fertility Societies (IFFS) and The Japanese Society for Regenerative Medicine (JSRM) jointly held their conferences at the Tokyo International Forum. Various discussions on reproductive medicine took place internationally. We reaffirmed that our diagnostic technology under development is a unique, highly niche technology with significant market needs, scale, and social significance, despite its uniqueness.

<HR>

Since our founding, infuse Life Science has engaged with several experts in the medical device industry on a contractual basis. We are pleased to officially welcome Kikuo Iwasaka, Shinichi Matsuno, Hiromi Ohsone, and Masuko Saito to our team, bringing our total number of members to eight.

Please see our team member page for more details:

https://infuselifescience.com/staff